Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-122517
- Development stage
- Unknown
- Lead developer
- HK inno.N Corporation
01
Overview
IN-122517: sourced facts only. name: "Here, we present our novel HPK1 inhibitor IN-122517 exhibiting good HPK1 inhibition potency and selectivity against 468 kinases including immune-related off-target kinases." [DOI:10.1158/1538-7445.am2025-2162]; target: "Here, we present our novel HPK1 inhibitor IN-122517 exhibiting good HPK1 inhibition potency and selectivity against 468 kinases including immune-related off-target kinases." [DOI:10.1158/1538-7445.am2025-2162]; developer: "HK inno.N Corporation, Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2025-2162]; stage: "Preclinical studies have shown beneficial tumor response to IN-122517 as a monotherapy and also improved efficacy when combined with anti-PD-1 monoclonal therapy." [DOI:10.1158/1538-7445.am2025-2162]
02
Targets
MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on IN-122517.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-122517.